Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC

July 20, 2022

Supplements and Featured Publications, Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC,

This AJMC^® publication explores the value of clinical oncology care pathways in non–small cell lung cancer (NSCLC) with insights from Edward Arrowsmith, MD, Medical Director for Pathways at OneOncology in Chattanooga, Tennessee.

Download Issue: Oncology Care Pathways Supporting the Use of High-value Treatments for NSCLC